Cell-based Cancer Immunotherapy
Series: Methods in Cell Biology; 183;
- Publisher's listprice EUR 160.00
-
66 360 Ft (63 200 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 13 272 Ft off)
- Discounted price 53 088 Ft (50 560 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
66 360 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 5 March 2024
- ISBN 9780443139956
- Binding Hardback
- No. of pages318 pages
- Size 234x190 mm
- Weight 1020 g
- Language English 542
Categories
Long description:
Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered in this volume include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more.
Additional sections cover Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies, Methods behind TCR analyses for colorectal cancer-associated TILs, The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, Humanized mouse models for anti-cancer therapy, In vitro re-challenge of CAR T cells, Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy, and A murine glioblastoma platform to test cellular therapies with the standard of care.
Table of Contents:
1. Methods behind clinical DC vaccine products against glioblastoma
Rï¿1⁄2diger V. Sorg
2. Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy
Jolanda de Vries and Gerty Schreibelt
3. Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Stefaan W. Van Gool
4. Identification of TCR repertoire patterns linked with anti-cancer immunotherapy
Kris Laukens and Romi Vandoren
5. Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells
Eva Lion and Kris Laukens
6. Methods behind neoantigen predictions for anticancer vaccines
Cedric Bogaert
7. Methods behind CD137L-DC-EBV-VAX anticancer vaccine
Herbert Schwarz
8. Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies
Dmitri Krysko
9. Methods behind TCR analyses for colorectal cancer-associated TILs
Sara Verbandt, Ting Pu and Sabine Tejpar
10. The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays
Adam Snook
11. Humanized mouse models for anti-cancer therapy
Eleonora Leucci
12. In vitro re-challenge of CAR T cells
Sebastien Walchli and Alicia Villatoro
13. Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy
Harry D. Bear and Carolyn Haynes
14. A murine glioblastoma platform to test cellular therapies with the standard of care
An Coosemans and Aaron Ziani Zeryouh Jr.
